2-AG	2-arachidonoylglycerol
AD	Alzheimer’s disease
AEA	anandamide
ALIA	Autacoid Local Injury Antagonism
BBB	blood-brain barrier
CA1	cornu Ammonis 1
CA3	cornu Ammonis 3
CB1	cannabinoid receptor type 1
CB2	cannabinoid receptor type 2
CCDRS	Canine Cognitive Dysfunction Rating Scale
CCDS	canine cognitive dysfunction syndrome
ccSDAT	Canine counterpart of senile dementia of Alzheimer’s type
CD33	Cluster of differentiation 33
CDS	cognitive dysfunction syndrome
CNS	central nervous system
COX-2	cyclooxygenase-2
D.I.S.H.A.	Disorientation, altered Interactions, Sleep-wake cycle changes, breaking in the House soiling and altered Activity levels
FAAH	fatty acid amide hydrolase
GPR18	orphan G-protein coupled receptors 18
GPR55	orphan G-protein coupled receptors 55
IL-1β	interleukin-1β
iNOS	inducible nitric oxide synthase
LTP	Long Term Potentiation
MCI	mild cognitive impairment
MRI	magnetic resonance imaging
PEA	palmitoylethanolamide
PPARα	peroxisome proliferator-activated receptor-α
PPARγ	peroxisome proliferator-activated receptor-γ
REM	rapid eye movement
TNFα	tumor necrosis factor α
TREM2	triggering receptor expressed on myeloid cells 2
TRPV1	transient receptor potential vanilloid type 1 channel
um-PEA	ultramicronized palmitoylethanolamide